Katya B Naidu &Amp; P B Jayakumar

Stories by Katya B Naidu &Amp; P B Jayakumar

R-Power raises $1 bn from 3 Chinese banks

R-Power raises $1 bn from 3 Chinese banks

Rediff.com   25 Jul 2008

Reliance Power (R-Power), the Reliance-ADAG group company, which plans to set up 28,000 mw of power plants in India, has secured $1 billion (or around Rs 4,200 crore) funding from three Chinese banks for the Sasan ultra mega power project (UMPP) in Madhya Pradesh.

ADAG firms vie with each other for coal project

ADAG firms vie with each other for coal project

Rediff.com   24 Jul 2008

In partnership with different US firms, two companies belonging to Reliance Anil Dhirubhai Ambani Group (ADAG) have submitted competing bids for a single project floated by the Ministry of Coal.

India Inc bets big on N-power

India Inc bets big on N-power

Rediff.com   24 Jul 2008

Indian companies led by Anil Ambani's Reliance Power (RPower), Nuclear Power Corporation of India (NPCIL) and Bharat Heavy Electricals (BHEL) plan to invest over Rs 100,000 crore in the next five years to expand their presence in the nuclear energy sector after the country signs the nuclear agreement with the US, paving the way for import of fuel and transfer of technology.

Drug firms may stop freebies to doctors

Drug firms may stop freebies to doctors

Rediff.com   23 Jul 2008

Pharmaceutical companies in the country offering any financial incentive to doctors to prescribe particular drugs may become a thing of the past if the drug manufacturers decide to follow the strict code of conduct being implemented by a US industry trade group.

Glenmark gears up for US acquisition

Glenmark gears up for US acquisition

Rediff.com   22 Jul 2008

Glenmark Pharmaceuticals (Glenmark), which reorganised its speciality and generics businesses recently, is looking to acquire a medium to large-scale speciality pharmaceutical company in the US.

Now, Pfizer, Novartis, GSK under USFDA scanner

Now, Pfizer, Novartis, GSK under USFDA scanner

Rediff.com   19 Jul 2008

Amid reports of a US Congress probe against India's largest drug maker Ranbaxy Laboratories, data show that many leading multinational companies such as Pfizer, GlaxoSmithKline, Novartis and Merck are also under the scanner of the US drug regulator, for more or less similar violations as Ranbaxy is alleged to have committed.

Pharma Q1 show to stay robust

Pharma Q1 show to stay robust

Rediff.com   17 Jul 2008

The pharmaceutical industry is expected to continue with its good performance in the first quarter of 2008-09 with over 25 per cent growth in revenues and about 45 per cent rise in net profit riding on better sales in the domestic and export markets. The industry will gain from the the depreciation of rupee as well.

3 Ranbaxy units face ban if US charges are proved

3 Ranbaxy units face ban if US charges are proved

Rediff.com   15 Jul 2008

Experts said it is the first time that an Indian pharmaceutical company has been charged with such serious offences, and that the firm may be prosecuted if the allegations are proved. Able Labs of the US, now a unit of Sun Pharma through an acquisition in 2005, had to face similar charges in 2004-2005.

US sues Ranbaxy for forging data

US sues Ranbaxy for forging data

Rediff.com   14 Jul 2008

Pharma major denies charges, to file response soon.

Suzlon to buy Chinese wind energy firm

Suzlon to buy Chinese wind energy firm

Rediff.com   8 Jul 2008

Tanti, who acquired Germany's REpower Systems last year, today announced plans to buy Chinese wind energy company Honiton Energy Holdings. The acquisition will be concluded through Colossus Holdings, a Singapore-based holding company of the Tanti group, and Bahrain-based private equity company Arcapita Bank for over $500 million (Rs 2,162 crore), sources said.

Ranbaxy, others to scrap 60 drug combinations

Ranbaxy, others to scrap 60 drug combinations

Rediff.com   7 Jul 2008

The voluntary move comes a little more than a year after the Central Drugs Standard Control Organisation, the central authority that approves new drugs for marketing, had asked the drug makers to withdraw the 'combination drugs' as they are 'unnecessary' and may pose health hazards. The Drugs Controller General of India had banned 294 combination drugs sold under nearly 1,053 brand names from the market in June 2007.

Ranbaxy deal may spur hostile bids in India

Ranbaxy deal may spur hostile bids in India

Rediff.com   12 Jun 2008

Aurobindo pharma, cipla, orchid chemicals are the prominent takeover targets.

Unwell? Get counselling before treatment

Unwell? Get counselling before treatment

Rediff.com   6 Jun 2008

Health experts point out that it will take decades for India to reach the level of health education and infrastructure in developed countries. Our per capita health expenditure is estimated at $23, which is only 6.1 per cent of the gross domestic production.

Wanbury eyes contract research firms in US

Wanbury eyes contract research firms in US

Rediff.com   16 May 2008

"We are looking at targets with a bottom line of Rs 50-60 crore (Rs 500-600 million) to expand our CRAMS business in various markets," said Ashok Shinkar, director, Wanbury. The company plans to increase its turnover to over Rs 900 crore (Rs 9 billion) within the next three years.

Pharmaceutical firms opt for inlicensing

Pharmaceutical firms opt for inlicensing

Rediff.com   15 May 2008

According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases. According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases.

Novartis' Voveran regains top position

Novartis' Voveran regains top position

Rediff.com   5 May 2008

Voveran, Novartis India's flagship pain killer medicine, has become the largest selling domestic drug with sales of more than Rs 11 crore (Rs 110 million) in March 2008, displacing Pfizer India's cough and cold syrup Corex, which had sales of Rs 10 crore (Rs 100 million). Cipla, on the other hand, maintained its leadership position as the largest domestic pharmaceutical company edging out Ranbaxy Laboratories with a market share of 5.24 per cent.

Bad times for pharmacy chains in India

Bad times for pharmacy chains in India

Rediff.com   28 Apr 2008

Even as a heated debate goes on in the corridors of power and academic circles on the impact of large retail chains on small shops, in one sector it is clear that the big players are close to biting dust. At least two large pharmacy chains are up for sale, industry sources said. Some others have shaken up their top management, while a few have cut back on their expansions. One is trying to rediscover its business model by looking at rural markets. And all are woefully short o

R-Power's Butibori project to begin soon

R-Power's Butibori project to begin soon

Rediff.com   24 Apr 2008

The 300 mw Group Captive Power Project (GCPP) being set up by Vidarbha Industries Power (VIPL), a special purpose vehicle (SPV) formed by Reliance Power, at Butibori near Nagpur in Maharashtra, will soon enter the construction phase. Sources said the required land has been acquired and the Maharashtra Pollution Control Board (MPCB) has given the green signal for setting up the project. Reliance Power will soon award the EPC contract for the Rs 1500 crore project.

'Ranbaxy will gain from Orchid's R&D'

'Ranbaxy will gain from Orchid's R&D'

Rediff.com   23 Apr 2008

Ranbaxy Laboratories on Tuesday announced a business alliance with Orchid Chemicals and Pharmaceuticals across multiple geographies and therapies, for finished dosage formulations and bulk drugs. The new alliance will explore new products and markets without disturbing the existing alliances. The deal is independent of any commitment related to management control and is a pure arm's length, independent strategic biz alliance. Ranbaxy will benefit from Orchid's future products

Tatas to set up ayurveda centre

Tatas to set up ayurveda centre

Rediff.com   21 Apr 2008

In a move to catapult ayurveda to the main stream of healthcare in the country, the Tata Group is setting up the Indian Institute of Ayurveda Integrated Medicine in Bangalore. The institute will function in association with the Department of Science and Technology, and the Foundation for Revitalisation of Local Health Traditions, a Bangalore-based NGO that supports traditional healing methods.